Also Included In: Cancer / Oncology; GastroIntestinal / Gastroenterology
Article Date: 14 Aug 2013 - 0:00 PDT Current ratings for:
Potential new anti-cancer target: 'dark-horse' molecule
Australian researchers have identified a molecule called interleukin-11 as a potential new target for anti-cancer therapies.
Until now, the importance of interleukin-11 in cancer development has been underestimated, but researchers have recently identified this molecule as a 'dark horse' for the development of cancer. Their discovery suggests blocking interleukin-11 signalling could ultimately provide an exciting new approach to the treatment of bowel and stomach cancer, which are two of the most common cancers worldwide.
When a tumour develops, the normal (non-cancerous) tissues around it can become inflamed, and produce many different molecules, including the two related proteins interleukin-11 and interleukin-6. These hormone-like signalling molecules, referred to as cytokines, are thought to promote the growth and spread of cancer cells, but interleukin-11 was thought to have only a minor, if any, role during cancer development.
However Dr Tracy Putoczki and Associate Professor Matthias Ernst from the Walter and Eliza Hall Institute's Cell Signalling and Cell Death division have now shown that interleukin-11 is one of the most important cytokines that stimulate the growth and spread of cancers. Working with scientists at the Melbourne-based pharmaceutical company CSL Ltd, they discovered that blocking interleukin-11 in models of stomach and bowel cancer stopped tumour growth and could lead to tumour shrinkage, making this cytokine a promising potential new target for treating many types of solid cancers.
Dr Putoczki and Associate Professor Ernst made most of their discoveries while working at the Melbourne-Parkville Branch of the Ludwig Institute for Cancer Research, where Associate Professor Ernst is an institute member. Their findings are published online in the journal Cancer Cell.
Dr Putoczki said the team was stunned to discover that interleukin-11 was much more potent in promoting cancer development than interleukin-6. "When considering which cytokines drive cancer development, interleukin-6 has always been in the spotlight," she said. "Despite being very similar to interleukin-6, interleukin-11 has often been overlooked by cancer researchers. Our new research now shows that it might in fact be very important."
Associate Professor Ernst said the team had begun to explore how the discovery could be applied to potential new anti-cancer therapies. "Treating cancers with agents that block cytokine signalling is an exciting new approach that potentially has advantages over current treatment strategies," he said. "Drugs that block the action of cytokines have previously been developed for both inflammatory disease and cancer and, in the case of interleukin-11, our work does not suggest the likelihood of undesirable side-effects. Moreover, agents that inhibit interleukin-6 signalling are already in clinical trials for ovarian, kidney, prostate and breast cancer. Our discovery paves the way for trials of agents that stifle interleukin-11."
Dr Andrew Nash, senior vice president for research at CSL, agreed that the research had identified a potentially important role for interleukin-11 in stomach and bowel cancer. "We have developed a number of potential drug candidates that target the interleukin-11 receptor and this data provides preclinical evidence supporting progression into clinical studies," Dr Nash said.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.Visit our colorectal cancer section for the latest news on this subject.
The research was supported by the Ludwig Insitute of Cancer Research, CSL Ltd, the Australian National Health and Medical Research Council, Cancer Australia, Cure Cancer Australia, German Cancer Aid, and the Victorian Government.
Interleukin-11 Is the Dominant IL-6 Family Cytokine during Gastrointestinal Tumorigenesis and Can Be Targeted Therapeutically Cancer Cell, Volume 24, Issue 2, 257-271, 12 August 2013. 10.1016/j.ccr.2013.06.017
Walter and Eliza Hall Institute
Ludwig Institute for Cancer Research
Please use one of the following formats to cite this article in your essay, paper or report:MLA
14 Aug. 2013.
Please note: If no author information is provided, the source is cited instead.
'Potential new anti-cancer target: 'dark-horse' molecule'
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
No comments:
Post a Comment